Document is current
Any future updates will be listed below
-
Authors
Loehrer, Philipp Alexander
Freigang, Julia
Bopp, Miriam H. A.
Calvano, Alexander
Dafsari, Haidar S.
Wichmann, Julius
Seidel, Amelie
Aberle, Carolin
Knake, Susanne
Nimsky, Christopher
Timmermann, Lars
Belke, Marcus
Pedrosa, David J.
-
Funding
Funding for this research was provided by:
Philipps-Universität Marburg
Thiemann Stiftung
EU Joint Programme – Neurodegenerative Disease Research
- License Information
-
More Information
Article History
Received: 28 September 2024
Accepted: 31 March 2025
First Online: 21 April 2025
Change Date: 30 June 2025
Change Type: Update
Change Details: This article has been updated to amend the license information.
Competing interests
: P.A.L. was supported by the SUCCESS-Program of the Philipps-University of Marburg, the ‘Stiftung zur Förderung junger Neurowissenschaftler’, and the Professor Klaus Thiemann Foundation in the German Society of Neurology. J.F. reports no financial disclosures. M.Bo is a scientific consultant for Brainlab. A.C. has participated in a training course which was industry-funded by Stada Arzneimittel A.G. H.S.D. was funded by the EU Joint Program—Neurodegenerative Disease Research (JPND), the Prof. Klaus Thiemann Foundation in the German Society of Neurology, the Felgenhauer Foundation, the KoelnFortune program of the Medical Faculty of the University of Cologne and has received honoraria by Everpharma, Kyowa Kirin, Bial, Oruen, and Stadapharm. J.W. reports no financial disclosures. AS reports no financial disclosures. C.A. reports no financial disclosures. S.K. reports no financial disclosures. C.N. is a scientific consultant for Brainlab. L.T. received payments as a consultant for Medtronic Inc. and Boston Scientific and received honoraria as a speaker on symposia sponsored by Bial, Zambon Pharma, UCB Schwarz Pharma, Desitin Pharma, Medtronic, Boston Scientific, and Abbott. The institution of L.T., not L.T. personally, received funding from the German Research Foundation, the German Ministry of Education and Research, and Deutsche Parkinson Vereinigung. M.Be reports no financial disclosures. DJP has received honoraria for speaking at symposia sponsored by Boston Scientific Corp, Medtronic, AbbVie Inc, Zambon and Esteve Pharmaceuticals GmbH. He has received honoraria as a consultant for Boston Scientific Corp and Bayer, and he has received a grant from Boston Scientific Corp for a project entitled “Sensor-based optimization of Deep Brain Stimulation settings in Parkinson’s disease” (COMPARE-DBS). The institution of DJP, not DJP personally, has received funding from the German Research Foundation, the German Ministry of Education and Research, the International Parkinson Foundation, the Horizon 2020 program of the EU Commission, and the Pohl Foundation in Marburg. Finally, DJP has received travel grants to attend congresses from Esteve Pharmaceuticals GmbH and Boston Scientific Corp.
